Inquiry Basket
Loading ......
Filter By Product Search for
TYMS
TYMS Full Name
thymidylate synthetase
TYMS Introduction
Thymidylate synthase (TYMS) is a central enzyme in nucleotide metabolism that directly addresses a fundamental challenge in cell biology and oncology: how cells sustain DNA synthesis and rapid proliferation. TYMS catalyzes the reductive methylation of deoxyuridine monophosphate (dUMP) to generate deoxythymidine monophosphate (dTMP), the sole de novo source of thymidine required for DNA replication and repair. Because this reaction sits at a critical metabolic checkpoint, even subtle changes in TYMS activity can disrupt DNA integrity and cell cycle progression. For researchers and clinicians, TYMS represents more than a housekeeping enzyme—it is a highly actionable molecular target whose expression level often determines whether proliferating cells, especially cancer cells, survive or undergo replication stress and apoptosis.
Functionally, TYMS operates at the intersection of metabolism, gene regulation, and therapeutic response, making it particularly relevant for those struggling with inconsistent drug efficacy in cancer treatment. Its expression is tightly controlled at transcriptional and post-transcriptional levels, including regulation by polymorphisms in the 5' untranslated region (5' UTR), such as the well-characterized 2R/3R variable number tandem repeat (VNTR). These genetic variations influence TYMS mRNA stability and protein abundance, which in turn modulate sensitivity to antifolate and fluoropyrimidine drugs like 5-fluorouracil (5-FU) and methotrexate (MTX). High TYMS expression is frequently associated with drug resistance, while lower expression may enhance therapeutic response but also increase toxicity risk. Emerging evidence further highlights interactions between TYMS and microRNAs, adding another regulatory layer that can influence treatment outcomes and complicate patient stratification in precision medicine.
Clinically, TYMS has evolved into a critical biomarker and therapeutic target in oncology, particularly in colorectal, gastric, breast, and hematological malignancies, where treatment resistance remains a major unmet need. Overexpression of TYMS has been consistently linked to poor prognosis and reduced responsiveness to standard chemotherapies, prompting the development of direct TYMS inhibitors such as novel oral agents designed to induce thymidine depletion and trigger DNA damage–mediated cell death. Beyond its canonical metabolic role, recent studies suggest that TYMS may contribute to oncogenesis through involvement in DNA replication fidelity and chromosomal stability, as well as interactions with the tumor immune microenvironment. These expanded functions highlight TYMS not only as a metabolic enzyme but also as a multifunctional driver of cancer biology, reinforcing its value as both a predictive biomarker and a strategic target for next-generation anticancer therapies.
Alternate Names for TYMS
TYMS; thymidylate synthetase; TS; TMS; HST422; thymidylate synthase; TSase;
Loading ......
